Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 12% of the time (146 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-04-10. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: disordersusemorphineexposureof drugs
  Phrases that lowered it: evaluate theto evaluateor equalsymptomaticblood pressure
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Keywords listed: 22 (raises risk) · Design
• Minimum age: not given (lowers risk) · Who can join
• Responsible party: sponsor investigator (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Maximum age: 0.02 (raises risk) · Who can join
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports marked serious: 76.4% (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants NCT01360450 · started 2011 · scored riskier than 66% of active trials terminated
• Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women NCT01965704 · started 2014 · scored riskier than 58% of active trials completed
• Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome NCT03670160 · started 2018 · scored riskier than 47% of active trials completed
• Improving Outcomes in Neonatal Abstinence Syndrome NCT01958476 · started 2013 · scored riskier than 59% of active trials completed
• Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome NCT01452789 · started 2011 · scored riskier than 72% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.